Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.

Christina Lau, 23 Jun 2020

Patients with coronavirus disease 2019 (COVID-19) have significant gut dysbiosis that persists even after viral clearance and resolution of respiratory symptoms, according to a metagenomic study by the Chinese University of Hong Kong (CUHK). These findings have led to the development of a probiotic supplement expected to be available in a few months.

Novel diagnostic tool PLUS accurate for detecting acute pneumonia in elderly adults

12 Sep 2020

A novel diagnostic tool, called the Pneumonia Lung Ultrasound Score (PLUS), is an easy, biomarker-derived, and accurate method for detecting acute pneumonia in the very old, a recent study has found.

Researchers conducted a prospective, single-centre cohort analysis of 132 elderly adults (mean age, 85.3±6.9 years; 69 percent female) who underwent chest X rays (CXR) and lung ultrasound (LUS). PLUS was defined as LUS with biomarkers such as the brain natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), and partial pressure arterial oxygen/fraction of inspired oxygen ratio (PaO2/FIO2).

LUS emerged as a better diagnostic tool than CXR, particularly in patients with multidimensional prognostic index (MPI) scores 0.33–0.66 (diagnostic accuracy, 0.97 vs 0.72; p=0.04) and >0.66 (diagnostic accuracy, 1.00 vs 0.64; p=0.003). MPI is an indicator of short- and long-term mortality, as well as of frailty.

In turn, PLUS was significantly superior in detecting acute pneumonia relative to LUS (area under the curve [AUC], 0.92 vs 0.86; p=0.029) and CXR (AUC, 0.92 vs 0.67; p<0.0001). Removing BNP from the PLUS model slightly weakened its diagnostic value, though it remained significantly better than LUS (AUC, 0.91; p=0.039 vs LUS).

In the PLUS scheme, each 100-unit drop in PaO2/FIO2 was worth one point, as was each 10-ng/mL increase in hs-CRP. An increase in BNP of 500 pg/mL was worth –0.5 points. The risk of pneumonia increased by a factor of two with every 1-unit increase in the PLUS score (odds ratio, 2.26, 95 percent confidence interval, 1.71–2.99).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.

Christina Lau, 23 Jun 2020

Patients with coronavirus disease 2019 (COVID-19) have significant gut dysbiosis that persists even after viral clearance and resolution of respiratory symptoms, according to a metagenomic study by the Chinese University of Hong Kong (CUHK). These findings have led to the development of a probiotic supplement expected to be available in a few months.